Left ventricular noncompaction (LVNC) describes a ventricular wall anatomy characterized by prominent left ventricular (LV) trabeculae, a thin compacted layer, and deep intertrabecular recesses. Individual variability is extreme, and trabeculae represent a sort of individual "cardioprinting." By itself, the diagnosis of LVNC does not coincide with that of a "cardiomyopathy" because it can be observed in healthy subjects with normal LV size and function, and it can be acquired and is reversible. Rarely, LVNC is intrinsically part of a cardiomyopathy; the paradigmatic examples are infantile tafazzinopathies.
. This more cautious, descriptive approach is the expression of clinical uncertainty regarding the unique interpretation of LVNC as a CMP (7) . The requirements for the definition of a CMP in the American Heart Association guidelines indicate, "disease of the myocardium associated with mechanical and/or electrical dysfunction" (4) , whereas the European Society of Cardiology guidelines define a CMP as "myocardial disease characterized by structurally and functionally abnormal heart muscle and absence of other diseases sufficient to cause the observed myocardial abnormality" (5) . By itself, the diagnosis of LVNC is made on the basis of one of the attributes that define CMPs, namely the abnormal LV morphology, but does not obligatorily imply abnormal LV function (7) .
In normal hearts, trabeculae actively provide mechanical leverage during early systolic ejection through contraction (8, 9) .
Trabeculae are formed during early embryonic development. The origin of LVNC is attributed to arrested compaction of the endomyocardial layer of the heart during early embryogenesis (8) . This hypothesis may explain typical LVNC cardiomyopathies, such as infantile tafazzinopathies, in which both LVNC and LV dilation and dysfunction are part of the same disease (10) , or LVNC in congenital heart disease (CHD) (11) . The embryogenesis hypothesis is difficult to reconcile in acquired (12) (13) (14) (15) (16) (17) (18) (19) and potentially reversible (15, 17) LVNC. In fact, LVNC can be an incidental finding in screening studies (i.e., athletes) (15) and is not associated with deterioration in LV volumes or function during long-term follow-up in the asymptomatic population (20) . The proportion of LVNC in asymptomatic subjects is increasingly described; up to 8% of consecutive athletes fulfill echocardiographic criteria for LVNC (15) . Multiparametric evaluation (electrocardiography, echocardiography, maximal stress test, 24-h Holter monitoring, and cardiac magnetic resonance [CMR] ) can contribute to discriminate benign LVNC (18) , which may represent a physiological adaptation to exercise conditioning and may be regarded as part of the spectrum of athlete's heart (21) .
Cardiologists facing isolated LVNC morphology have to decide if they are observing a "CMP" or a variant of the LV wall anatomy. In most cases, especially in adult patients, the key element in the diagnostic decision is not the LVNC by itself, but the associated LV dilation and/or dysfunction, hypertrophy, right ventricular involvement, arrhythmias, and conduction disease. This review critically discusses the current knowledge on genetic LVNC as both an isolated trait and as part of other cardiac diseases or complex syndromes.
LVNC: THE DIAGNOSIS
The extreme variability of the LV trabecular anatomy is the manifestation of individual, dynamic "car- The diagnostic criteria were created on the basis of ratios between thickness (25, 26) , mass (27) , or volume (28) 
Genetics in LVNC
A U G U S T 3 0 , 2 0 1 6 : 9 4 9 -6 6 Lack of consensus on uniformly accepted standards of diagnosis influences both epidemiology and interpretation of imaging data. The prevalence of "hypertrabeculation" and LVNC is increasingly reported in large echocardiographic series (20) . Overdiagnosis is one of the risks of forcing a morphologic marker in rigid numbers/ranges, being aware that the individual variability of the trabecular anatomy is vast. The opposite risk is underdiagnosing and missing early CMPs. Unfortunately, other diagnostic tools do not help; although commonly abnormal in LVNC associated with CMP, electrocardiography does not by itself contribute to the specific diagnosis of LVNC.
LVNC AS ISOLATED AND NONISOLATED
TRAIT/DISEASE LVNC can be regarded as an isolated entity or as one of the traits that may recur in cardiac and noncardiac diseases. As a marker, it can suggest specific diagnoses; that is, tafazzinopathies (caused by mutations in the TAZ [Tafazzin, or G4.5] gene) in male infants with a dilated, hypokinetic phenotype (10, 39, 40) . As a structural trait with potential functional effects, it may contribute to LV dysfunction in coexisting morphofunctional disorders, such as CMP or CHD (Table 1 [ [34] [35] [36] ). On the basis of current knowledge and terminology, LVNC can be grouped as follows:
1. iLVNC. NC morphology is observed in left ventricles with normal systolic and diastolic function, size, and wall thickness (20) . The genetic basis of iLVNC in otherwise normal hearts is unknown. LVNC can be:
• Dynamic, changing with disease progression
• Emerging during the course of the disease
• Potentially reversible
Hearts with normal LV size and function:
• Individual variability
Genetic LVNC associated with:
• Chromosomal anomalies
• Monogenic syndromes
• Congenital heart diseases
• Cardiomyopathies
Non-genetic LVNC also reported in:
• Athletes
• Sickle cell anemia Arbustini et al.
A U G U S T 3 0 , 2 0 1 6 : 9 4 9 -6 6
Genetics in LVNC to cardiologists for consultation. The latter are complex syndromes that display several multiorgan defects; chromosomal abnormalities include deletions, translocations, and trisomy or tetrasomy. 6. Acquired and potentially reversible iLVNC, which has been reported in athletes (15, 18, 19) ; it has also been reported in sickle cell anemia (14, 16) , pregnancy (17) , myopathies (12) , and chronic renal fail- Overall, the morphofunctional context in which the LVNC is observed is, by itself, heterogeneous, in terms of both heart diseases and systemic or multiorgan disorders, depending on the type of syndrome 
In blue: 9 of the 10 left ventricular noncompaction (LVNC) phenotypes (#1, [3] [4] [5] [6] [7] [8] [9] [10] Table 2) .
LVNC GENES
The genes reported to date in at least 1 patient/family with LVNC are listed in Table 1 (34-36 The heart has normal left ventricular diameter and left ventricular function. The 2 genetic variants identified in TXNRD2 and in MYBPC3 cannot be further investigated in family segregation studies because the patient is adopted. The TXNRD2 gene encodes a selenocysteine-containing enzyme that is essential for mitochondrial oxygen radical scavenging. Mutations in this gene have been reported in dilated cardiomyopathy (118) .
The variant in MYBPC3 is common and unlikely to be the cause of the left ventricular noncompaction. The morpho-functional description is according to MOGE(S) nosology (6).
CTA ¼ computed tomography angiography.
Arbustini et al. showing only LV wall hypertrabeculation. The morpho-functional description is according to MOGE(S) nosology (6) .
Genetics in LVNC the diagnosis is driven by the congenital heart defect. These genes code for sarcomeric proteins, nuclear envelope and Z-band components, sarcolemma proteins, ion channels, and genes involved in signaling pathways, such as NOTCH ( Table 1) . Arbustini et al.
A U G U S T 3 0 , 2 0 1 6 : 9 4 9 -6 6 Cardiologic work-up includes individual examination, medical history (arrhythmias, syncope), family history (affected family members, SD of relatives) and screening, 12-lead ECG, 2D echocardiography. When indicated and possible: CMR with gadolinium contrast. Possible: stress echocardiography, $ 24-h Holter monitoring for arrhythmias. Personalized work-up contributes to tailoring individual clinical investigation. Monitoring should be planned in patients with cardiomyopathy or CHD associated with LVNC as well as in asymptomatic subjects in whom LVNC/hypertrabeculation has been identified.
No indication to anticoagulation. Possible participation in competitive sports (112) Anticoagulation in patients with LV dilation and dysfunction as per guidelines; atrial dilation; cardiac surgery related indications in CHD.
Anticoagulation: to be decided on individual needs in patients with LV dilation and dysfunction.
Anticoagulation in patients with ventricular dilation and dysfunction and atrial dilation. 
The affected family members demonstrate different phenotypes: the proband (IV:2) displays dilated cardiomyopathy (DCM) þ LVNC and his father (III:2) shows dilated HCM, as do both his grandmother (II:2) and great-grandmother (I:4). This latter was the unique family member who had Mahaim fibers and tachycardia. She died at 88 years of age after a 30-year history of cardiomyopathy. In the proband, the left ventricular thickness (short-axis view) is normal (9 mm), left ventricular end-diastolic diameter is increased (58 mm), and left ventricular ejection fraction is 48%. His genetic profile is unique in the family: he inherited both the ACTC1 mutation and the VUS in DSC2 from the father and a further VUS in LAMA2 from the mother, who demonstrated normal LV size, morphology, and function. The role of the ACTC1 mutation seems to be confirmed by its segregation with the cardiomyopathy; the role of the DSC2 and LAMA2 variants is unclear. LVNC appears as a sporadic trait, whereas the cardiomyopathy is familial autosomal dominant. The morpho-functional description is according to MOGE(S) nosology (6).
Abbreviations as in Figure 4 .
Arbustini et al.
Genetics in LVNC The proband underwent heart transplantation for dilated cardiomyopathy; the heart excised at transplantation revealed left ventricular noncompaction, mostly because of the near absence of the compacted layer. Onset of the illness had occurred 10 years before transplantation with an episode of syncope sustained by ventricular tachycardia. The evolving phenotype was as in a biventricular dilated cardiomyopathy. The parents are consanguineous. We identified a MYBPC3 mutation that does not segregate with the phenotype because the carrier father is unaffected; in addition, both sister and brother are carriers of the same variant and have normal hearts. We also identified a rare splice variant in Ion-channel genes (e.g., SCN5A), genes encoding calcium-release channels (e.g., the ryanodine recep- However, when LVNC is associated with dilated or hypertrophic phenotype, the diagnosis should be driven by the type of CMP, followed by the description of LVNC. 
Genetics in LVNC characterized by evolution through LV dilation and dysfunction, similar to DCM. LVNC may occur but is uncommon (75, 76 The need for consensus on diagnostic criteria from the scientific societies;
Cautious diagnostic labeling of iLVNC as a CMP;
The need for observational, prospective registries including probands and relatives with LVNC. 
